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Abstract: Background: Stereotactic body radiotherapy (SBRT) in ultra-central (UC) lung tumors,
defined in the presence of planning target volume (PTV) overlap or direct tumor abutment to the
central bronchial tree or esophagus, may be correlated to a higher incidence of severe adverse events.
Outcome and toxicity in oligometastatic (≤3 metastases) non-small-cell lung cancer (NSCLC) patients
receiving SBRT for UC tumors were evaluated. Methods: Oligometastatic NSCLC patients treated
with SBRT for UC were retrospectively reviewed. Local control (LC), distant metastasis-free survival
(DMFS), progression-free survival (PFS) and overall survival (OS) were calculated. Incidence and
grade of toxicity were evaluated. Statistical analysis was performed to assess the impact of clinical
and treatment-related variables on outcome and toxicity occurrence. Results: Seventy-two patients
were treated to a median biologically effective dose (BED) of 105 (75–132) Gy10. Two-year LC, DMFS,
PFS, and OS were 83%, 46%, 43%, and 49%. BED>75 Gy10 was correlated to superior LC (p = 0.02),
PFS (p = 0.036), and OS (p < 0.001). Grade ≥3 toxicity rate was 7%, including one fatal esophagitis.
No variables were correlated to DMFS or to occurrence of overall and grade ≥3 toxicity. Conclusions:
SBRT using dose-intensive schedules improves outcome in NSCLC patients. Overall toxicity is
acceptable, although rare but potentially fatal toxicities may occur.
Keywords: non-small-cell lung cancer; ultra-central; stereotactic radiotherapy; oligometastases;
biologically effective dose
1. Introduction
Lung cancer is among the most frequent malignancies worldwide and is burdened by a high
disease-related mortality [1]. About 85% of cases are non-small-cell lung cancer (NSCLC) [1,2].
For patients with oligometastatic disease, defined as ≤3 or fewer concurrent metastases [3], use of
ablative local treatments may improve outcome: multiple treatment options have been applied in
this setting, including surgery, radiofrequency, and stereotactic radiotherapy (SBRT) [4]. Surgical
therapy, the treatment of reference for oligometastases in historical series, has been extensively
described for adrenal, lung, and brain metastases [5–8], but its use is traditionally limited to selected
candidates [7,9]. Use of radiofrequency ablation may be limited by its invasive nature, with consequent
risk of complications such as pneumothorax and bleeding [10]. Due to its noninvasive character
and possibility to treat multiple targets during the same treatment course, SBRT emerged in the last
decade as a valuable treatment option, resulting in excellent local control rates and possible survival
benefits [11,12]. However, tumor location influences the indication to treatment and the choice of dose
regimen in patients eligible to SBRT: life-threatening adverse events, such as broncho-esophageal fistulae
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and hemorrhage, have been reported in patients undergoing SBRT on central tumors (defined as tumors
located within 2 cm of the proximal bronchial tree, heart, great vessels, trachea, or other mediastinal
structures), if an ablative dose is delivered in three fractions [13]. Conversely, use of more protracted
dose schedules (4–12 fractions) showed an acceptable toxicity incidence with satisfying oncologic
outcomes [14–18]. Recently, a subset of proximally-seated central tumors, dubbed “ultra-central”,
has been reported as a separate clinical entity due to possible additional increased risk of fatal
toxicity [19]. However there is no consensual definition of "ultra-central" tumors. Chaudhuri et al.
classified central tumors as "ultra-central" if the gross tumor volume (GTV) directly invaded the proximal
bronchial tree or trachea [20], and the same definition has also been used by Haseltine et al. [21].
On the other hand, Tekatli et al. defined as ultra-central those tumors for which the planning target
volume (PTV) overlaps the trachea or main bronchi [22]. Recently, a more consensual definition
was introduced in the prospective dose-finding SUNSET trial, enrolling patients with tumors ≤6 cm
whose PTV touches or overlaps the central bronchial tree, esophagus, pulmonary vein, or pulmonary
artery [23]. Finally, controversy arose about the most suitable dose and fractionation schedule for the
treatment of ultra-central tumors due to stringent trade-offs between the need for an ablative dose
delivery (traditionally corresponding to a biologically effective dose of 100 Gy for lung tumors [24])
and risk of radiation injury in case of over-irradiation of proximal critical structures; Tekatli et al.
reported a 15% fatal toxicity rate (mainly due to pulmonary hemorrhage) in patients with ultra-central
tumors who received a treatment regimen delivering 60 Gy in 12 fractions [22]. The aim of our study
is to evaluate the safety and efficacy of different SBRT regimens for the treatment of ultra-central
NSCLC oligometastases and to assess the predictive influence of clinical and treatment-related factors
on outcome and incidence of toxicity.
2. Results
2.1. Patient- and Treatment-related Characteristics
Patient- and treatment-related characteristics are summarized in Table 1. Median follow-up per
patient from SBRT completion was 17 months (interquartile range, IQR 8–24 months). Median age at
SBRT was 75 years (IQR 67–80 years). Histologic subtypes were adenocarcinoma and squamous cell
carcinoma in 75% (n = 54) and 25% (n = 18) of patients, respectively. In the majority of cases (n = 70,
98%), the PTV encompassed the central bronchial tree, at the level of the main bronchi (n = 36, 50%) and
the lobar bronchi (n = 34, 48%). The PTV–esophagus overlap occurred in two patients (2%). Systemic
therapy, excluding adjuvant chemotherapy for primary cancer, was administered prior to SBRT in 27
patients (38%), consisting of 1 or ≥2 chemotherapy lines in 28% (n = 20) and 10% (n = 7) of patients,
respectively. Different dose regimens were used, consisting of 50 Gy/5 fractions, 45 Gy/6 fractions,
48–60 Gy/8 fractions, and 50–70 Gy/10 fractions radiation schedules in 18%, 10%, 61%, and 11% (n = 13,
7, 44, 8) of patients, respectively. Median prescribed biologically effective dose (BED) was 105 Gy10
(range 75–132 Gy10).
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Table 1. Clinical and treatment-related variables and impact on local control, distant metastases-free survival, progression-free survival, and overall survival. NR: not
reached; BED: biologically effective dose. Italic: variable type. Bold: significant at statistical analysis (p < 0.05).
Clinical and Treatment-Related Variables Local Control p Distant Metastases-FreeSurvival p
Progression-Free
Survival p
Overall
Survival p
Age (median 75 years, range 43–85)
< 75 years (n = 38, 53%) Median NR
0.3
18 months
0.73
18 months
0.47
Median NR
0.20≥75 years (n = 34, 47%) Median NR 16 months 14 months 27 months
Disease site
Juxtabronchial (n = 70, 98%) Median NR
0.6
18 months
0.13
17 months
0.16
Median NR
0.58Paraesophageal (n = 2, 2%) Median NR 5 months 5 months Median NR
Histotype
Adenocarcinoma (n = 54, 75%) Median NR
0.98
16 months
0.48
12 months
0.35
Median NR
0.41Squamous Cell Carcinoma (n = 18, 25%) Median NR 17 months 17 months Median NR
Timing of Metastatic Dissemination
Synchronous (n = 47, 65%) Median NR
0.44
18 months
0.87
18 months
0.67
Median NR
0.17Metachronous (n = 25, 35%) Median NR 14 months 11 months Median NR
Gross Tumor Volume (median 60 cc, range 7–400 cc)
< 60 cc (n = 37, 52%) Median NR
0.24
28 months
0.88
16 months
0.60
Median NR
0.09≥60 cc (n = 35, 48%) Median NR 16 months 17 months Median NR
Prior Chemotherapy
Naïve (n = 45, 62%) Median NR
0.84
44 months
0.003
44 months
0.008
Median NR
0.15≥ 1 line (n = 27, 38%) Median NR 7 months 7 months Median NR
BED (median 105, range 75–132 Gy10)
<75 Gy10 (n = 67, 93%) Median NR
0.02
6 months
0.24
6 months
0.036
Median NR
<0.001≥75 Gy10 (n = 5, 7%) Median NR 18 months 17 months 6 months
Overall Treatment Time
≤1 week (n = 13, 18%) Median NR
0.69
Median NR
0.43
Median NR
0.34
Median NR
0.9
>1 week (n = 59, 82%) Median NR 16 months 16 months Median NR
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2.2. Local Control
At three months from SBRT, ORR was 91%, consisting of SD, PR, and CR in 27%, 30%, and 33% of
patients respectively. Rates of LC were 91% at one year and 83% at two years; median not reached
(Figures 1A and 2). At univariate analysis, only the administration of a BED > 75 Gy10 was significantly
associated (p = 0.02) with improved LC (see Table 1).Cancers 2020, 12, x 3 of 13 
 
 
Figure 1. Kaplan–Meier plots for: (A) local control (LC). (B) distant metastases-free survival (DMFS). 
(C) progression-free survival (PFS). (D) overall survival (OS). 
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At one and two years, DMFS was 58.5% and 46%, respectively, with a median of 18 months (95% 
CI 10–53) (Figure 1B). At univariate analysis, patients previously treated with chemotherapy showed 
poorer DMFS as compared to chemotherapy-naïve patients (7 versus 44 months, p = 0.003). PFS rates 
were 57% and 43% at one and two years, respectively, with a median of 17 months (95% CI 10–46) 
(Figure 1C). At univariate analysis, BED >75 Gy10 was correlated with improved PFS (17 versus 6 
months, p = 0.036), while prior use of chemotherapy was associated with poorer PFS (7 versus 44 
months, p = 0.008) (Table 1). Multivariate analysis confirmed the independent prognostic impact of 
BED >75 Gy10 (hazard ratio, HR: 0.25, 95% CI 0.07–0.88; p = 0.03) and prior use of chemotherapy (HR 
2.44, 95% CI 1.25–4.75; p = 0.009).  
2.4. Overall Survival 
At one and two years, OS was 84% and 49%, respectively, with a median of 22 months (Figure 
1D). At univariate analysis, BED >75 Gy10 correlated with improved survival: 24 versus 7 months, p < 
0.001 (Table 1). 
Figure 1. Kaplan–Meier plots for: (A) local control (LC). (B) distant metastases-free survival (DMFS).
(C) progression-free survival (PFS). (D) overall survival (OS).
2.3. Progression-Free Survival
At one and two years, DMFS was 58.5% and 46%, respectively, with a median of 18 months
(95% CI 10–53) (Figure 1B). At univariate analysis, patients previously treated with chemotherapy
showed poorer DMFS as compared to chemotherapy-naïve patients (7 versus 44 months, p = 0.003).
PFS rates were 57% and 43% at one and two years, respectively, with a median of 17 months (95% CI
10–46) (Figure 1C). At univariate analysis, BED >75 Gy10 was correlated with improved PFS (17 versus
6 months, p = 0.036), while prior use of chemotherapy was associated with poorer PFS (7 versus
44 months, p = 0.008) (Table 1). Multivariate analysis confirmed the independent prognostic impact of
BED >75 Gy10 (hazard ratio, HR: 0.25, 95% CI 0.07–0.88; p = 0.03) and prior use of chemotherapy (HR
2.44, 95% CI 1.25–4.75; p = 0.009).
2.4. Overall Survival
At one and two years, OS was 84% and 49%, respectively, with a median of 22 months (Figure 1D).
At univariate analysis, BED >75 Gy10 correlated with improved survival: 24 versus 7 months, p < 0.001
(Table 1).
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Figure 2. Patient with a clinical history of pT2N0 lung adenocarcinoma treated with upper lobe lobectomy. A: Paramediastinal middle lobe metastasis (12 × 13 mm) 
detected at follow-up contrast-enhanced chest CT. B: 18FDG-PET/CT fusion showing isolated hypermetabolism of the paramediastinal metastasis . C: SBRT 
delivering 50 Gy in five fractions to the PTV (dark blue: 20 Gy; light blue: 30 Gy; green: 40 Gy; yellow: 45 Gy; red: 50 Gy). D: CT evaluation at nine months showing 
radiation fibrosis following complete metabolic response. 
Figure 2. Patient with a clinical history of pT2N0 lung adenocarcinoma treated with upper lobe lobectomy. A: Paramediastinal middle lobe metastasis (12 × 13 mm)
detected at follow-up contrast-enhanced chest CT. B: 18FDG-PET/CT fusion showing isolated hypermetabolism of the paramediastinal metastasis. C: SBRT delivering
50 Gy in five fractions to the PTV (dark blue: 20 Gy; light blue: 30 Gy; green: 40 Gy; yellow: 45 Gy; red: 50 Gy). D: CT evaluation at nine months showing radiation
fibrosis following complete metabolic response.
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2.5. Toxicity
Report of toxicities is summarized in Table 2. Treatment-related adverse effects, all grade
confounded, were observed in 30% of the patients: this consisted, in most cases, of mild grade
1–2 radiation pneumonitis (15%) and esophagitis (6%), as well as two cases of minor, spontaneously
resolving hemoptysis. However, severe toxicity (grade ≥3) occurred in five cases, consisting mostly of
radiation pneumonitis or hemoptysis requiring medical intervention and admission at the emergency
department. At statistical analysis, no variable was correlated with the onset of overall or grade
≥3 toxicity (see Table 3). One patient experienced respiratory failure following stenosis of the main
bronchus requiring endoscopic dilatation after fine needle aspiration excluded a disease recurrence.
Finally, one possible grade 5 toxicity was reported in a 76-year-old patient with a clinical history of
resected pT1a lung adenocarcinoma, who underwent SBRT (delivering 50 Gy in five fractions) to a
lung metastasis located in proximity to the main left bronchus. During the following three months,
she experienced a severe deterioration of her general conditions linked to painful dysphagia and cachexia
ultimately leading to anorexia and death. A contrast-enhanced CT detected a massive intramediastinal
relapse, resulting in a possible mass effect on the feeding tube; however, esophagogastroduodenoscopy
showed an ulcerated bleeding esophageal mucosa, as well as extrinsic compression, thus a possible
component related to radiation injury could not be excluded (Figure 3).
Table 2. Summary of toxicity. CTCAE: Common Terminology Criteria for Adverse Events.
CTCAE Grade Radiation Pneumonitis Hemoptysis Radiation Esophagitis Bronchial Stricture
1 5 (7%) 0 (0%) 1 (2%) 0 (0%)
2 6 (8%) 2 (3%) 3 (5%) 0 (0%)
3 2 (3%) 1 (2%) 0 (0%) 0 (0%)
4 0 (0%) 0 (0%) 0 (0%) 1 (2%)
5 0 (0%) 0 (0%) 1 (2%) 0 (0%)
Table 3. Clinical and treatment-related variables and impact on overall and grade ≥3 toxicity. NR: not
reached; BED: biologically effective dose. Italic: variable type.
Clinical and Treatment-Related Variables
Overall Toxicity
p
Grade ≥3 Toxicity
p
No Yes No Yes
Age (median 75 years, range 43–85)
<75 years 27 (38%) 11 (15%)
0.81
37 (51%) 1 (1%)
0.53≥75 years 25 (35%) 9 (12%) 30 (42%) 4 (6%)
Disease site
Juxtabronchial 51 (71%) 19 (27%)
0.93
65 (90%) 5 (8%)
0.69Paraesophageal 1 (1%) 1(%) 2 (2%) 0
Histotype
Adenocarcinoma 36 (50%) 18 (25%)
0.73
50 (69%) 4 (6%)
0.97Squamous Cell Carcinoma 14 (19%) 4 (6%) 17 (24%) 1 (1%)
Timing of Metastatic Dissemination
Synchronous 34 (47%) 13 (18%)
0.98
42 (58%) 5 (8%)
0.09Metachronous 18 (25%) 7 (10%) 25 (34%) 0
Gross Tumor Volume (median 60 cc, range 7–400 cc)
<60 cc 23 (32%) 14 (19%)
0.07
37 (51%) 3 (5%)
0.51≥60 cc 27 (37%) 8 (12%) 30 (42%) 2 (2%)
Prior Chemotherapy
Naive 32 (44%) 13 (18%)
0.79
41 (57%) 4 (6%)
0.29≥ 1 line 20 (28%) 7 (10%) 27 (37%) 0
BED (median 105, range 75–132 Gy10)
<75 Gy10 48 (66%) 19 (27%)
0.91
63 (86%) 4 (6%)
0.65≥75 Gy10 4 (6%) 1 (1%) 5 (8%) 0
Overall Treatment Time
≤1 week 8 (11%) 5 (8%)
0.53
12 (17%) 1 (1%)
0.75
>1 week 44 (61%) 15 (20%) 56 (78%) 3 (4%)
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Figure 3. Patient with a clinical history of pT1aN0 lung adenocarcinoma treated with lingulectomy. A: Histologically-proven adenocarcinoma metastasis (34 mm) 
of the left paravertebral space, treated with SBRT (purple: GTV; red: PTV). B: SBRT delivering 50 Gy in five fractions to the PTV (dark blue: 20 Gy; light blue: 30 Gy; 
green: 40 Gy; yellow: 45 Gy; red: 50 Gy). C: Esophageal endoscopy following painful dysphagia and cachexia: extrinsic compression from tumor relapse associated 
to ulcerated mucosal ulceration possibly related to radiation treatment. 
Figure 3. Patient with a clinical history of pT1aN0 lung adenocarcinoma treated with lingulectomy. A: Histologically-proven adenocarcinoma metastasis (34 mm) of
the left paravertebral space, treated with SBRT (purple: GTV; red: PTV). B: SBRT delivering 50 Gy in five fractions to the PTV (dark blue: 20 Gy; light blue: 30 Gy;
green: 40 Gy; yellow: 45 Gy; red: 50 Gy). C: Esophageal endoscopy following painful dysphagia and cachexia: extrinsic compression from tumor relapse associated to
ulcerated mucosal ulceration possibly related to radiation treatment.
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3. Discussion
Here we report outcome and toxicity data on 72 patients affected by ultra-central oligometastases
from NSCLC primaries. With an aggressive approach, we report excellent LC rates (91% at one year and
83% at two years), while DMFS and PFS are in line with the clinical scenario presented, confirming that
distant relapse is the most common pattern of disease relapse in oligometastatic patients receiving
ablative local therapy.
An increasing body of literature is now supporting the use of local ablative approaches with
curative intent in oligometastatic patients, the most convincing data arising from the group of NSCLC
patients [11,25,26]. Nevertheless, in clinical situations such as the occurrence of ultra-central lung
oligometastases, the delivery of SBRT to radical doses can be technically challenging.
Since the pivotal trials of SBRT for lung tumors, it emerged quite clearly that the incidence of
toxicity observed in cases of tumors located within 2 cm around the proximal bronchial tree was
significantly higher as compared to peripheral tumors, while using the same doses and number of
fractions [13]. Various attempts have been conducted to identify a less aggressive, although equally
effective, stereotactic treatment regimen for central tumors, showing that the delivery of a BED > 100 Gy
in five or more fractions resulted in a safe and effective treatment, with results similar to those obtained
for peripheral targets [15–17,27,28]. However, scarce data are available concerning the treatment of
ultra-central tumors, for which it is still unclear whether these fractionation schedules can be used
with the same tolerance and efficacy. Among future strategies, expanding use of proton therapy and
hadrons (for example, carbon ion) may allow potential dosimetric advantage over photon-based SBRT
in reducing dose exposure of critical structures while maintaining target tumor dose coverage. In a
recent meta-analysis by Chi et al., a lower incidence of grade ≥3 toxicity was associated with the use of
particle therapy (0.9% vs. 3.4%, p = 0.001) [29].
In our study, although most patients were treated with a BED > 75 Gy10, toxicity was manageable,
with only one case of suspected G5 toxicity reported and five cases of G3 toxicity fully recovered
following medical treatment. In most patients, SBRT was well tolerated. Along with this, we also
observed high tumor control rates, with a significant impact of delivered dose: in patients receiving
a BED of 75 Gy10 (corresponding to 50 Gy in 10 fractions, a schedule proposed for ultra-central
tumors [30]), the local control rate was significantly lower. While some authors advocate for dose
de-escalation to a BED ≤ 60 Gy10 in ultra-central tumors in an effort to prioritize safety of the organs
at risk (OARs), the use of low-dose regimens results in inferior tumor control rates, with two-year
LC 59%–70% [31,32]. Our results stress the need for sufficiently intensive dose-regimens in order
to warrant durable disease control. The relevance of the delivered dose can also be extrapolated by
another recent series, including patients with ultra-central lung tumors treated with a median BED of
59.5 Gy. Twenty-four out of 51 patients developed a local recurrence, with a one-year local control rate
of 54.4%, compared with 91% as shown in our study [33].
Most notably, we found that delivering an ablative dose to the ultra-central metastases can change
the course of the disease, since the PFS was 6 times longer in patients treated with BED >75 Gy and
a significant impact on OS was also identified. This observation stresses the need for an ablative
treatment regimen in oligometastatic patients, even in the event of ultra-central localization.
Our data are consistent with those published by Chang et al. in 2018. Authors evaluated
107 patients with primary and metastatic central and ultra-central tumors treated with five-fraction
schedules. The author found no difference in LC, OS, and grade ≥3 toxicity comparing patients with
central and ultra-central tumors [34]. A recent review analyzed data from 10 studies focusing on SBRT
for ultra-central lung tumors, for a total number of 250 treated patients [19]. Despite obvious limitations
linked to the retrospective nature of the study and the heterogeneity of delivered doses (BED ranging
from 48 to 138 Gy), safety was confirmed. Median treatment-related grade 3 or greater toxicity was 10%
(range, 0%–50%). Median treatment-related mortality rate was 5%. Authors also reported that higher
doses to the proximal bronchial tree, concurrent bevacizumab use, and antiplatelet/anticoagulant
use were correlated with increased toxicity. In our series, we were not able to find any significant
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correlation between analyzed variables and toxicity, probably due to the small study population and
the low number of events that occurred. Apart from the BED, we also found prior administration of
chemotherapy as a strong determinant of PFS. Indeed, chemotherapy-naïve patients had a median PFS
of 44 months compared to 7 months in patients who had already received at least one chemotherapy
line. Although counter-intuitive, this parameter is starting to be more and more present in the literature
of oligometastatic patients, since it is a simple and immediate surrogate of the advancement of the
disease. Chemotherapy-naïve patients are more frequently at an earlier stage of their disease and may
exhibit a more radiosensitive phenotype in comparison to heavily-pretreated patients, resulting in
longer disease remission intervals. In a large series of oligometastatic patients from different primaries
and various sites, the administration of systemic therapies prior to SBRT predicted a higher risk of
progression, with an HR of 1.19 [35]. Similarly, Sharma et al. reported poorer local control in patients
previously treated with chemotherapy in a large database of 327 pulmonary oligometastases from
miscellaneous primary tumors [36].
Despite the well-known limitations of a retrospective study and the heterogeneity of treatment
regimens, our experience is one of the largest published series on oligometastatic ultra-central tumors
by NSCLC. The results we report are very satisfactory in terms of safety and local control and confirm
that ablative doses are required in the oligometastatic setting, as far as reasonably acceptable, and have
a real impact on the patients‘ prognosis.
4. Materials and Methods
4.1. Patient Selection, Treatment Procedures, and Follow-up
Ultra-central tumors were defined as tumors for which the planning target volume(PTV) touches
or overlaps the following organs at risk (OARs): central bronchial tree, esophagus, pulmonary
vein, or pulmonary artery [23]. Oligometastatic disease was defined as three or fewer concurrent
metastases. According to these criteria, 72 consecutive patients undergoing SBRT for ultra-central
NSCLC oligometastases from February 2013 to July 2019 were identified, accounting for 72 treated
tumors. For all patients, pathological confirmation with a biopsy was obtained at the diagnosis or at
the first disease relapse. Indication to treatment was discussed at the Multidisciplinary Tumor Board.
In all cases, a 1.5-mm-thick slice simulation 4D CT was acquired, and an internal target volume (ITV)
was delineated to take into account respiratory motion of the gross tumor volume (GTV). PTV was
obtained by an isotropic expansion of 5 mm of the ITV. An assessment of efficacy was performed using
the revised Response Evaluation Criteria In Solid Tumors (RECIST version 1.1, 2009). Incidence of
toxicity was evaluated using the Common Terminology Criteria for Adverse Events (CTCAE version
4.03, 2010). A clinical evaluation with a physical examination and CT-scan was performed every
three months or in presence of clinical symptoms: in case of suspicious CT progression, additional
confirmation by 18FDG-PET or targeted biopsy may be required. Informed consent was obtained by
all the patients or relatives (in case of deceased patients), and investigations were conducted according
to Declaration of Helsinki principles. The study was carried out according to the national regulation
on biomedical research (study n◦2114/ID733).
4.2. Definition of the Endpoints
The objective response rate (ORR) was defined as the presence of stable disease (SD),
partial response (PR), or complete response (CR) at the first CT re-evaluation at three months.
Local failure (LF) was defined as an increase of ≥20% in the diameter of the target lesion. Local control
(LC) was calculated from SBRT completion to the date of LF or the last follow-up. Distant metastasis-free
survival (DMFS) was measured from SBRT completion until the onset of distant metastases outside the
irradiated area. Progression-free survival (PFS) was defined as the delay between SBRT completion
and disease progression at any site. Overall survival (OS) was measured from SBRT completion until
death from any cause or last follow-up.
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4.3. Statistical Analysis
Clinical (age, proximity OAR, histological subtype, timing of metastases from primary tumor
diagnosis, tumor size) and treatment-related (prior chemotherapy, total delivered dose, overall treatment
time) variables were summarized using descriptive statistics. To allow for comparison among different
dose regimens, all radiation doses were expressed as biologically effective dose according to the formula
total dose × [1 + (dose per fraction/(α/β))], assuming an α/β of 10 for NSCLC (BED). Survival plots were
calculated using the Kaplan–Meier method. Univariate analysis using the log-rank test was performed
to investigate the predictive impact of dichotomized categorical variables on outcome. The Cox
multivariate model was applied in case of multiple predictive factors that were found significant at
univariate analysis. The correlation between variables and overall or severe (CTCAE grade ≥ 3) toxicity
was investigated using the chi2-test. A p-value ≤0.05 was considered statistically significant. Statistical
analysis was performed using MEDCalc statistical software version 19.0.3 (MedCalc Software bvba,
Ostend, Belgium).
5. Conclusions
SBRT for ultra-central lung tumors in oligometastatic NSCLC is safe, with a low incidence of
severe toxicity. The delivery of ablative doses is required to avoid local progression and may change
the natural history of the disease.
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